Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2007

01-12-2007 | Short communication

Oxford Overview

Author: James N Ingle

Published in: Breast Cancer Research | Special Issue 2/2007

Login to get access

Excerpt

The Early Breast Cancer Trials Collaborative Group (EBCTCG) is a global organization of trialists that has conducted randomized clinical trials of therapies in early breast cancer. This organization, with its Data Management and Analysis Center in Oxford, England, has conducted meta-analyses of a variety of therapies, producing information that is not available from individual trials. This process has become known as the Oxford Overview. …
Literature
1.
Anonymous: Review of mortality results in randomized trials in early breast cancer. Lancet. 1984, 2: 1205-
2.
Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef
3.
Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005, 366: 2087-2106.CrossRef
4.
LHRH-agonists in Early Breast Cancer Overview group: Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet. 2007, 369: 1711-1723. 10.1016/S0140-6736(07)60778-8.CrossRef
Metadata
Title
Oxford Overview
Author
James N Ingle
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1822

Other articles of this Special Issue 2/2007

Breast Cancer Research 2/2007 Go to the issue

Short communication

Do classical oestrogen markers predict for clinical response to endocrine therapy?

Short communication

Clinical outcomes: to be a surrogate or not to be ...?

Section introduction

Introduction to clinical research sessions

Short communication

The origins of oestrogen receptor negative breast cancer

Short communication

Short-term presurgical treatment for all?

Short communication

The oestrogen paradox: an hypothesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits